June 24, 2022
1 min watch
Save
VIDEO: Integrating sequential immunotherapy to lung cancer treatment plans
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Melina Marmarelis, MD, highlights findings from a Lung-MAP nonmatched substudy presented at ASCO Annual Meeting.
“The idea of sequential immunotherapy is something that we’re all grappling with in this era of multiple different immunotherapies approved in different lines,” Marmarelis, assistant professor of medicine at University of Pennsylvania, said.
Reference:
- Reckamp KL, et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.